GoAI
Get started
SkinHealth Systems Inc. logo

SkinHealth Systems Inc.

SKIN

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$0.6533

+$0.0233 · +3.70%

Aug 21, 4:00 PM ET

SKIN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

36

Weakening

Sentiment

52

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Pedro Malha
Listed since
Nov 24, 2020
Employees
613

Market position

Day range

Current $0.6533

52-week range

Current $0.6533

Open
$0.631
Previous close
$0.63
Volume
388.19K
0.18× average
Average volume
2.11M
Average daily volume
Market cap
84.67M USD
Beta
1
Market reference 1
50-day average
$0.7254
-9.94% below average
200-day average
$1.0325
-36.73% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
321.67M USD
P/E (TTM)
-2.9×
P/B (TTM)
1.52×
P/S (TTM)
0.29×
EV / EBITDA
8.3×
Earnings yield
-5.42%
Free cash flow yield
18.40%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
66.34%
Operating margin
-1.49%
Net margin
-9.79%
Return on equity
-15.58%
Return on assets
-1.90%
Return on invested capital
-4.70%

Financial health

Debt / equity
6.6×
Current ratio
1.66×
Altman Z-score
-0.48
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%4%-81%-167%Gross margin, FY2021: 68.65%Gross margin, FY2022: 68.00%Gross margin, FY2023: 38.97%Gross margin, FY2024: 54.53%Gross margin, FY2025: 65.28%Operating margin, FY2021: -15.35%Operating margin, FY2022: -7.06%Operating margin, FY2023: -32.89%Operating margin, FY2024: -20.27%Operating margin, FY2025: -6.92%Net margin, FY2021: -145.63%Net margin, FY2022: 12.09%Net margin, FY2023: -25.16%Net margin, FY2024: -8.70%Net margin, FY2025: -3.16%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.65%. Gross margin FY2022 68.00%. Gross margin FY2023 38.97%. Gross margin FY2024 54.53%. Gross margin FY2025 65.28%. Operating margin FY2021 -15.35%. Operating margin FY2022 -7.06%. Operating margin FY2023 -32.89%. Operating margin FY2024 -20.27%. Operating margin FY2025 -6.92%. Net margin FY2021 -145.63%. Net margin FY2022 12.09%. Net margin FY2023 -25.16%. Net margin FY2024 -8.70%. Net margin FY2025 -3.16%.

Income trends

Revenue

300.79M USD-10.02%

Operating income

−20.8M USD+69.31%

Net income

−9.52M USD+67.29%
Income trends across reported periods475.67M USD164.96M USD−145.74M USD−456.44M USDRevenue, FY2021: 260.09M USDRevenue, FY2022: 365.88M USDRevenue, FY2023: 397.99M USDRevenue, FY2024: 334.29M USDRevenue, FY2025: 300.79M USDOperating income, FY2021: −39.93M USDOperating income, FY2022: −25.84M USDOperating income, FY2023: −130.92M USDOperating income, FY2024: −67.77M USDOperating income, FY2025: −20.8M USDNet income, FY2021: −378.76M USDNet income, FY2022: 44.22M USDNet income, FY2023: −100.12M USDNet income, FY2024: −29.1M USDNet income, FY2025: −9.52M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 260.09M USD. Revenue FY2022 365.88M USD. Revenue FY2023 397.99M USD. Revenue FY2024 334.29M USD. Revenue FY2025 300.79M USD. Operating income FY2021 −39.93M USD. Operating income FY2022 −25.84M USD. Operating income FY2023 −130.92M USD. Operating income FY2024 −67.77M USD. Operating income FY2025 −20.8M USD. Net income FY2021 −378.76M USD. Net income FY2022 44.22M USD. Net income FY2023 −100.12M USD. Net income FY2024 −29.1M USD. Net income FY2025 −9.52M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue300.79M USD334.29M USD397.99M USD365.88M USD260.09M USD
Cost of goods sold104.43M USD152M USD242.88M USD117.1M USD81.55M USD
Gross profit196.36M USD182.3M USD155.11M USD248.78M USD178.54M USD
Research and development5.63M USD6.3M USD10.1M USD8.44M USD8.2M USD
Selling, general, and administrative211.54M USD243.77M USD275.93M USD266.18M USD210.27M USD
Operating expenses217.17M USD250.07M USD286.03M USD274.62M USD218.47M USD
Interest income8.95M USD16.64M USD23.17M USD9.18M USD39K USD
Interest expense19.33M USD10.41M USD13.65M USD13.39M USD11.78M USD
Depreciation and amortization25.35M USD29.48M USD34.68M USD22.87M USD17.93M USD
Operating income−20.8M USD−67.77M USD−130.92M USD−25.84M USD−39.93M USD
Net income−9.52M USD−29.1M USD−100.12M USD44.22M USD−378.76M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+34.49%
11 comparable reports
Latest EPS result
-0.02
Estimate -0.03 · Beat by 20.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.190.07-0.05-0.17Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual -0.08, estimate -0.1, surprise +20.00%, Beat. Q2 2025, reported May 8, 2025: actual -0.08, estimate -0.13, surprise +38.46%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.15, estimate -0.06, surprise +350.00%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.09, estimate -0.08, surprise -12.50%, Miss. Q1 2026, reported Mar 12, 2026: actual -0.06, estimate -0.07, surprise +14.29%, Beat. Q2 2026, reported May 7, 2026: actual -0.05, estimate -0.09, surprise +44.44%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.02, estimate -0.025, surprise +20.00%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates86.84M77.82M68.79M59.77MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual 83.5M USD, estimate 77.19M USD, surprise +8.18%, Beat. Q2 2025, reported May 8, 2025: actual 69.6M USD, estimate 63.11M USD, surprise +10.28%, Beat. Q3 2025, reported Aug 7, 2025: actual 78.2M USD, estimate 74.54M USD, surprise +4.91%, Beat. Q4 2025, reported Nov 6, 2025: actual 70.7M USD, estimate 68.55M USD, surprise +3.14%, Beat. Q1 2026, reported Mar 12, 2026: actual 82.4M USD, estimate 78.2M USD, surprise +5.37%, Beat. Q2 2026, reported May 7, 2026: actual 64.9M USD, estimate 66.28M USD, surprise -2.08%, Miss. Q3 2026, reported Aug 6, 2026: actual 72.1M USD, estimate 74.45M USD, surprise -3.16%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 67.83M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

11 institutions
Roth CapitalmaintainBuy
JefferiesdowngradeBuyHold
William BlairdowngradeOutperformMarket Perform

SKIN news

zacks.com

SkinHealth Systems Inc. (SKIN) International Revenue Performance Explored

Examine the evolution of SkinHealth Systems Inc.'s (SKIN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Read source
defenseworld.net

Herbalife (NYSE:HLF) versus Beauty Health (NASDAQ:SKIN) Head to Head Comparison

Herbalife (NYSE: HLF - Get Free Report) and Beauty Health (NASDAQ: SKIN - Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on…

Read source
seekingalpha.com

SkinHealth Systems Inc. (SKIN) Q2 2026 Earnings Call Transcript

SkinHealth Systems Inc. (SKIN) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Beauty Health Q2 Earnings Call Highlights

Beauty Health NASDAQ: SKIN reported second-quarter revenue at the low end of its guidance range as cautious capital spending by providers continued to weigh on equipment sales, while stronger gross margins and expense…

Read source
zacks.com

SkinHealth Systems Inc. (SKIN) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for SkinHealth Systems Inc. (SKIN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street…

Read source
zacks.com

Earnings Preview: SkinHealth Systems Inc. (SKIN) Q2 Earnings Expected to Decline

SkinHealth Systems Inc. (SKIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read source

SKIN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SKIN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.7M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
634.24K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
257.98K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Schwab U.S. Broad Market ETF logoSchwab U.S. Broad Market ETFSCHB
Market value
130.75K
Weight
0.00%
AUM
44.6B USD
Expense ratio
0.03%
Price / 1D
$29.61+0.48%

Continue in GoAI

Research SKIN

research.disclaimer